Get a weekly digest of the latest psychedelic research, new studies, and platform updates delivered to your inbox.
No spam, ever. Unsubscribe anytime.
Substance Profile
6-APB (6-(2-aminopropyl)benzofuran) is a benzofuran derivative that acts as a serotonin-norepinephrine-dopamine releaser, producing MDMA-like entactogenic effects. Originally developed by David Nichols as a research tool. 6-APB has a longer duration than MDMA (6-8 hours) and a somewhat more psychedelic profile due to higher 5-HT2A affinity. It is considered potentially less neurotoxic than MDMA and is being investigated as a possible therapeutic alternative.
No subjective effects data available yet.
No linked studies yet.